Introduction
Two recent announcements show the Government’s intent to improve the UK as a location for clinical research and boost our life sciences sector. This article summarises the announcements and provides context.
Prime Minister “Turbocharges” Medical Research in the UK
On 7 April 2025, the Prime Minister announced a £600 million investment aimed at revolutionising medical research in the UK. This initiative, a collaboration between the Government and the Wellcome Trust, seeks to establish a new health data research service designed to enhance access to NHS data for researchers, expedite clinical trials, and improve patient care. The announcement stressed the importance of balancing this against stringent security and privacy standards.
Single point of access to national health datasets
The announcement promises a new health data research service which will provide a secure, single access point to national-scale NHS data sets, significantly reducing bureaucratic hurdles for researchers. This streamlined approach will enable faster and more efficient data analysis, facilitating the development of life-saving drugs and treatments. By consolidating data access into one secure location, researchers will no longer need to navigate multiple systems or submit multiple applications for the same project, which should improve the pace of medical research.
Fast-tracking clinical trials
The announcement also promises to fast-track clinical trials. The time required to set up clinical trials will be reduced from over 250 days to 150 days by March 2026. This will be achieved by cutting bureaucracy, standardising contracts across NHS organisations, and ensuring transparency through the publication of trust-level data. Standard contracting and reduced bureaucracy would be a big improvement – those are currently significant pain points for clinical researchers.
Detail?
The announcement was very light on detail. We will have to wait to see how these promises will be implemented. Some clues may be found in last year’s Sudlow Report, the main recommendations of which align with the Government’s announcement. The announcement has been cautiously welcomed by organisations such as the Health Research Authority (“HRA”) and Health Data Research UK, who stressed the importance of safety and building public trust. This will be particularly important after recent concerns about Chinese researchers accessing UK BioBank data.
Implementation of New Clinical Trial Regulations
As we previously reported, the UK is updating its clinical trial regulations to make them more attractive to researchers. Those regulations are now a step closer.
Implementation of new regulations begins
On 10 April 2025 Wes Streeting formally signed the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2024, beginning the twelve month implementation period, after which the new regulations will take full effect. This is just a few months later than originally anticipated.
The aim of the regulations is ultimately to make the UK more attractive for clinical research. In particular, the regulations aim to do so by reducing the regulatory burden and increasing flexibility and proportionality. They have been described by the HRA as the “most significant overhaul of UK clinical trial regulations in 20 years”.
In the implementation period, the Medicines and Healthcare Products Regulatory Authority and the HRA will be engaging with the sector to prepare for the new regulations, by providing guidance and training.
Conclusion
These two updates show a commitment to improve the conditions for clinical research in the UK. In both cases, the detail and the implementation will tell whether they are successful in realising the potential of the UK in this field. And in both cases, maintaining public safety and trust will be key. But it is good to see action being taken.
